Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone for Partial Adrenal Insufficiency After TBI or SAH
NCT01089075Phase 4Terminated
- Sponsor
- Max Planck Institute of Psychiatry
- Start
- Feb 2010
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hydrocortisone in adrenal insufficiency (AI) (2 arms), sponsored by Max Planck Institute of Psychiatry. Primary endpoint: Changes in score of alertness test (TAP) - interindividual differences at Day 14. Started Feb 2010; status: terminated.
02
Drugs
hydrocortisone
03
Conditions
adrenal insufficiency (AI)
Beyond the preview
Go deeper on NCT01089075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01089075.